stress, and comorbidities, among others.23 As such, it is important for treatment to recapture skin clearance after discontinuation and retreatment. The AMAGINE-1 phase 3 trial (NCT01708590) assessing the efficacy of brodalumab had a planned withdrawal phase at week 12 (patients were switched to placebo) with eligibility for retreatment starting at week 16 upon return of disease (defined as static physician’s global assessment score [sPGA] of 3 or greater). Patients who achieved PASI75 at week 12 and underwent withdrawal and retreatment exhibited recapture rates of 100%, 96.9%, and 84.4% in PASI75, PASI90, and PASI100 responses, respectively by week 24.24 Notably, recapture rates for PASI75 after withdrawal and retreatment for secukinumab and ixekizumab were 93.8% and 87.0%, respectively.25,26
Brodalumab Achieves Clearance as a Rescue Treatment
Despite the many successes of biologics in plaque psoriasis, treatment failure remains a significant problem for many patients and practitioners. Brodalumab has also been evaluated as a rescue therapy in patients who have lost response or developed intolerance to other biologic agents. The data for brodalumab as rescue therapy for ustekinumab and IL-17A inhibitor treatment failures are discussed next.
